Better Choice Research Partner, Aimia Pet HealthCo Inc., Signs R&D Partnership Agreement for Development of GLP1 Supplement for Pets
Retrieved on:
Wednesday, November 8, 2023
Faculty, NYSE, São Paulo, Federal University of Rio Grande do Sul, Obesity, Cat, Université de Montréal Faculty of Veterinary Medicine, Pet, Doctor of Philosophy, Rio, UNESP, APH, Veterinary medicine, MOU, Medical school, Faculty of Medicine, University of Colombo, University of São Paulo, UFRGS, Animal, University, Universidad, Overweight, Better Choice Parking, Pain management, GLP1, Dog, MS, Physiology, Medicine, Pharmacology, Anesthesia
TAMPA, Fla., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Better Choice Company (NYSE: BTTR) (“Better Choice” or the “Company”), a pet health and wellness company, and its research partner, Aimia Pet HealthCo Inc. (APH), today announced that APH has signed a memorandum of understanding (MOU) with Dr. Nadia Crosignani for the development of a GLP1 supplement for pets.
Key Points:
- TAMPA, Fla., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Better Choice Company (NYSE: BTTR) (“Better Choice” or the “Company”), a pet health and wellness company, and its research partner, Aimia Pet HealthCo Inc. (APH), today announced that APH has signed a memorandum of understanding (MOU) with Dr. Nadia Crosignani for the development of a GLP1 supplement for pets.
- The MOU sets out the basis for Dr. Crosignani to commence research and development of a GLP1 supplement for use in companion animals.
- In addition, Dr. Crosignani has a post-doctorate degree from UNESP, Faculty of Medicine, researching in the field of pain management.
- We see the use of the GLP1 supplement as a significant opportunity for the pet health industry and are assembling top tier partners to help Better Choice and our brands, including Halo, become pioneers in this sector,” commented Mike Young, Chairman of the Board for Better Choice.